Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Gordon

Showing results (781-790 of 800) with videos related to

Pageof 80
Sort By:
Blood Cancer Discovery|November 5, 2025
PKCβ Inhibitor MS-553 Displays Preclinical Efficacy in Both Treatment-Naïve and BTK Inhibitor-Resistant Chronic Lymphocytic LeukemiaBritten K Gordon, Elizabeth M Muhowski, Jyotsana Singh, et al.
The Lancet. Rheumatology|December 30, 2021
Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trialLorinda Chung, Cathie Spino, Richard McLain, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|May 19, 2025
Hand swelling and other non-Raynaud's symptoms as the initial presentation of systemic sclerosis: prevalence and clinical associations in two U.S. cohortsIqtidar Hanif, Shervin Assassi, Maureen D Mayes, et al.
NPJ Genomic Medicine|July 2, 2025
Geno4ME Study: implementation of whole genome sequencing for population screening in a large healthcare systemIsabelle A Lucas Beckett, Kate R Emery, Josiah T Wagner, et al.
ACR Open Rheumatology|November 26, 2025
Combining Pirfenidone With Mycophenolate Mofetil for Systemic Sclerosis-Related Interstitial Lung Disease (Scleroderma Lung Study III): An Investigator-Initiated, Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 TrialDinesh Khanna, Cathie Spino, Donald P Tashkin, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 26, 2019
Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase II Investigator-Initiated, Multicenter, Double-Blind, Randomized, Placebo-Controlled TrialDinesh Khanna, Cathie Spino, Sindhu Johnson, et al.
Arthritis Care & Research|April 20, 2026
Discordance between patient and physician global assessments in early systemic sclerosisEllen Romich, Alexis Ogdie, Alisa Stephens-Shields, et al.
Journal for Immunotherapy of Cancer|April 8, 2025
Consensus disease definitions for ophthalmic immune-related adverse events of immune checkpoint inhibitorsEileen L Chang, Renee Liu, Kiandokht Keyhanian, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|May 8, 2018
Brief Report: Whole-Exome Sequencing to Identify Rare Variants and Gene Networks That Increase Susceptibility to Scleroderma in African AmericansPravitt Gourh, Elaine F Remmers, Steven E Boyden, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 25, 2019
<i>HLA</i> and autoantibodies define scleroderma subtypes and risk in African and European Americans and suggest a role for molecular mimicryPravitt Gourh, Sarah A Safran, Theresa Alexander, et al.
Pageof 80

Showing results (781-790 of 800) with videos related to

Sort By:
Pageof 80
Blood Cancer Discovery|November 5, 2025
PKCβ Inhibitor MS-553 Displays Preclinical Efficacy in Both Treatment-Naïve and BTK Inhibitor-Resistant Chronic Lymphocytic LeukemiaBritten K Gordon, Elizabeth M Muhowski, Jyotsana Singh, et al.
The Lancet. Rheumatology|December 30, 2021
Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trialLorinda Chung, Cathie Spino, Richard McLain, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|May 19, 2025
Hand swelling and other non-Raynaud's symptoms as the initial presentation of systemic sclerosis: prevalence and clinical associations in two U.S. cohortsIqtidar Hanif, Shervin Assassi, Maureen D Mayes, et al.
NPJ Genomic Medicine|July 2, 2025
Geno4ME Study: implementation of whole genome sequencing for population screening in a large healthcare systemIsabelle A Lucas Beckett, Kate R Emery, Josiah T Wagner, et al.
ACR Open Rheumatology|November 26, 2025
Combining Pirfenidone With Mycophenolate Mofetil for Systemic Sclerosis-Related Interstitial Lung Disease (Scleroderma Lung Study III): An Investigator-Initiated, Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 TrialDinesh Khanna, Cathie Spino, Donald P Tashkin, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 26, 2019
Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase II Investigator-Initiated, Multicenter, Double-Blind, Randomized, Placebo-Controlled TrialDinesh Khanna, Cathie Spino, Sindhu Johnson, et al.
Arthritis Care & Research|April 20, 2026
Discordance between patient and physician global assessments in early systemic sclerosisEllen Romich, Alexis Ogdie, Alisa Stephens-Shields, et al.
Journal for Immunotherapy of Cancer|April 8, 2025
Consensus disease definitions for ophthalmic immune-related adverse events of immune checkpoint inhibitorsEileen L Chang, Renee Liu, Kiandokht Keyhanian, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|May 8, 2018
Brief Report: Whole-Exome Sequencing to Identify Rare Variants and Gene Networks That Increase Susceptibility to Scleroderma in African AmericansPravitt Gourh, Elaine F Remmers, Steven E Boyden, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 25, 2019
<i>HLA</i> and autoantibodies define scleroderma subtypes and risk in African and European Americans and suggest a role for molecular mimicryPravitt Gourh, Sarah A Safran, Theresa Alexander, et al.
Pageof 80